At what enterprise value was QUOTIENT SCIENCES acquired in 2019?

During the acquisition of QUOTIENT SCIENCES by PERMIRA in 2019, the transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b GBP.

When was QUOTIENT SCIENCES acquired by PERMIRA?

QUOTIENT SCIENCES was acquired by PERMIRA in 2019.

What was the revenue of QUOTIENT SCIENCES at the time of the deal?

The revenue of QUOTIENT SCIENCES at the time of the deal is estimated to be in the range of 100M - 200M GBP.

How is the data for the QUOTIENT SCIENCES acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the QUOTIENT SCIENCES deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.permira.com/portfolio/our-portfolio?sort=latest&filters%5Bsectors%5D%5B0%5D=healthcare

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaQUOTIENT SCIENCES

07/2019

QUOTIENT SCIENCES acquired by PERMIRA

UNITED KINGDOM Life Sciences / Pharma & Biotech / CDMO EV 500M - 1.5b GBP

Context

Permira acquired a majority stake in Quotient Sciences from GHO Capital, which had owned the business since 2015. Under GHO's four-year ownership, the company underwent a major transformation, expanding its service offering into commercial manufacturing and establishing a significant presence in the United States through strategic investments and acquisitions. The transaction provided GHO with a strong exit while securing new capital for Quotient to continue its international expansion.

QUOTIENT SCIENCES, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Quotient Sciences is a provider of outsourced drug development services. It is best known for its proprietary "Translational Pharmaceutics" platform, which integrates formulation development, real-time clinical manufacturing, and clinical pharmacology to accelerate the drug development process.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2019

2018

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2019	SAGARD	STERIMED	FRANCE	Medical Consumables
08/2019	PERMIRA	CAMBREX CORPORATION	UNITED STATES	CDMO
07/2019	BC PARTNERS	Synthon International	NETHERLANDS	Generics / Labs
07/2019	3I	IONISOS	FRANCE	CDMO
05/2019	ARDIAN	SINTETICA	SWITZERLAND	Pharma & Biotech
04/2019	EURAZEO	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Medical Devices
04/2019	ICG / MERIEUX EQUITY PARTNERS	DOC GENERICI	ITALY	Generics / Labs
12/2018	MERCK & CO.	ANTELLIQ	FRANCE	Animal Health
11/2018	ARDIAN	NEOPHARMED GENTILI	ITALY	Generics / Labs
10/2018	BRIDGEPOINT	HTL BIOTECHNOLOGY	FRANCE	CDMO

REFERENCES

Valuation range: EV 500M - 1.5b GBP

Revenue range: 100M - 200M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of QUOTIENT SCIENCES by PERMIRA are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: permira